CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationCD74-NRG1 Gene Fusion as a Bona Fide Oncogene

Overview of attention for article published in Molecular Cancer Therapeutics, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 10 X posts from 7 X users, with an upper bound of 3,513 followers.

NRG1 #GeneFusions are recurrent driver #oncogenes that cause oncogene dependency. Werr et al find that patients with NRG1 fusion-positive #cancers respond to therapy targeting the ERBB2:ERBB3 receptors. https://t.co/evUeZA01pX https://t.co/6J1rImO6HL

New article: CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization https://t.co/Ga7fGCtEXG #pancreaticcancer #oncology https://t.co/a41DVfFMYS

New article: CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization https://t.co/d8wiwadwQN #lungcancer #oncology https://t.co/o7paTsMVvI

RT @werr_li: Happy to share our manuscript @MCT_AACR and thanks a lot to all co-authors! @chr_reinhardt @DennisPlenker @braegelmannlab @ha…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.